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The understanding of gene function and its relevance to
human disease is one of the most important objectives
in the postgenome era. The most direct avenue to un-
covering this relationship is the positional cloning of
human disease genes, particularly for disorders with
Mendelian inheritance. Even when multiple mutational
mechanisms result in the same disorder, affected indi-
viduals from different families can be ascertained, to ﬁnd
those individuals with speciﬁc mutations on a single
gene. This provides solid evidence that mutation of a
gene is causative of the disease and gives important in-
formation regarding gene function.
The relationship between gene function and pheno-
type is not as clearly delineated in more-complicated
situations. In the case of contiguous-gene syndromes
caused by heterozygous gene deletions, it may be pos-
sible to use the extent of deletions to map the relevant
genes for speciﬁc phenotypes directly in the human.
However, speciﬁc deletion mechanisms may make the fre-
quency of certain deletions so high as to preclude detailed
deletion analysis, as is the case for DiGeorge syndrome/
velocardiofacial syndrome (DGS [MIM 188400]; VCFS
[MIM194230]). In DGS/VCFS, a heterogeneous disorder,
the majority of the patients have the same 3-Mb deletion,
whereas a small subset have a nested 1.5-Mb deletion,
and very few patients have different deletions from the
two common ones (Baldini 2002). In this situation, it
may be impossible to deﬁnitively assign a phenotypic
function to a gene on the basis of the extent of deletion.
As an alternative strategy, mouse models can be used
to determine the contribution of regions or even indi-
vidual gene mutations to a complicated phenotype in
contiguous-gene syndromes. Over distances of 1–2 Mb,
the order and gene content are often well conserved be-
tween syntenic segments in the human and the mouse
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although there are occasional inversions and loss of some
genes. Knockout mice can provide clues to gene function
and an entry point to modeling complex human phe-
notypes. In this review, we will discuss the prospects of
using the mouse to model a representative contiguous-
gene–deletion syndrome,Miller-Dieker syndrome (MDS).
Isolated Lissencephaly Sequence and MDS
Isolated lissencephaly sequence (ILS [MIM607432]) and
MDS (MIM 24720) are speciﬁc human malformation
syndromes, both of which exhibit classical lissencephaly,
literally “smooth brain.” Classical lissencephaly is a het-
erogeneous human developmental brain disorder caused
by defects in neuronal migration events that normally
occur at 9–13 wk of embryonic development. Lissenceph-
aly encompasses varying degrees of agyria or pachygyria
(the absence or thickening, respectively, of the convolu-
tions of the cerebral cortex). Grade 1 consists of complete
agyria, grades 2 and 3 describe mixed agyria/pachygyria,
and grade 4 consists solely of pachygyria (de Rijk-van
Andel et al. 1990). Classical lissencephaly is further char-
acterized by a thick cerebral cortex with disorganized
cortical layers, dysmorphic or hypoplastic corpus cal-
losum, generalized neuronal heterotopias, enlarged ven-
tricles, and microcephaly (Dobyns et al. 1983).
Individuals with ILS have lissencephaly of grades 2–4
but no other major malformations, whereas patients
with MDS have a more severe grade of lissencephaly
and display a characteristic dysmorphic facial appear-
ance. This includes prominent forehead with bitemporal
hollowing, short nose with upturned nares, thickened
upper lip with a thin vermilion upper border, widely
spaced eyes, low ears, and small jaw. MDS has been
associated with other abnormalities, including central
hypotonia, heart malformations, omphalocele, inguinal
hernia, duodenal atresia, pelvic and cystic kidneys,
sacral tails, cryptorchidism, polydactyly, clinodactyly,
camptodactyly, transverse palmar creases, and poly-
hydramnios during pregnancy (Dobyns et al. 1991). Pa-
tients with ILS or MDS exhibit mental and motor im-
pairment, epilepsy, and a reduced life span.
All cases of MDS and most cases of ILS are found to
be associated with haploinsufﬁciency on chromosome
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17p13.3. (Schwartz et al. 1988; Dobyns et al. 1991; Led-
better et al. 1992). Other cases of ILS are often asso-
ciated with mutations in the doublecortin gene, located
on chromosome Xq22.3-q23. In effect, all patients with
MDS and ∼40% of patients with ILS have visible or
submicroscopic deletions on 17p13.3 that are detectable
by FISH. The MDS deletions are generally larger and
more distal than those in patients with ILS. The LIS1
gene was cloned from the 17p13.3 region and was
found in certain patients with ILS to have either point
mutations or an intragenic deletion (Reiner et al. 1993).
This demonstrated that defects in LIS1 are responsible
for classical lissencephaly seen in patients with ILS
and MDS. The heterozygous deletions and mutations
of LIS1 suggest that proper neuronal migration is sen-
sitive to LIS1 gene dosage. Thus, haploinsufﬁciency is
the likely pathogenic mechanism, since there is no ev-
idence for imprinting of LIS1. The spectrum of agyria/
pachygyria in ILS is dependent on the location and type
of mutation in the LIS1 gene. Patients with missense
mutations have a milder grade, whereas truncation and
deletion mutations resulted in a more severe phenotype
(Cardoso et al. 2000).
The most severe form of lissencephaly (grade 1) and
other major MDS abnormalities are found only with
larger (1250 kb) and more-telomeric deletions on chro-
mosome 17p13.3, including and extending beyondLIS1
(Chong et al. 1997). This is consistent with MDS
being a contiguous-gene syndrome, in which deletion
of physically contiguous but functionally unrelated
genes causes a complex human genetic disease. There-
fore, it has been suggested that genes distal to LIS1may
be responsible for the facial dysmorphisms and other
abnormalities seen in patients with MDS. Since com-
plete agyria is seen only in MDS and not ILS, it has
also been hypothesized that a second gene located
within the MDS deletion may also be required for
proper neuronal migration. It is noteworthy that, for
17p13.3-linked diseases, the facial features of MDS
have not yet been seen without lissencephaly, and nei-
ther ILS nor MDS has been observed without LIS1 de-
letion or mutation. In addition, although deletions have
been documented that extend from LIS1 toward the
centromere, there appear to be no additional phenotypic
consequences to the extension of deletions beyond LIS1
(Chong et al. 1997). These data pose an interesting ques-
tion: Does deletion of individual genes telomeric toLIS1
contribute to speciﬁc MDS abnormalities, or are dele-
tions of LIS1 and a number of telomeric genes necessary
for the complete MDS phenotype?
In a recent study, detailed analysis using FISH was
performed on samples from 30 patients with ILS, ILS
with mild facial dysmorphisms (ILS), or MDS, to de-
termine the difference in deletion size and to identify
genes that may be responsible for the MDS phenotype
(Cardoso et al. 2003); Cardoso et al. showed that as the
deletion size increased, patients displayed more charac-
teristics ofMDS, such as facial dysmorphisms and amore
severe LIS grade. Furthermore, the facial abnormalities
seemed to indicate a more severe LIS grade. Patients with
ILS always had LIS grade 3 or 4; patients with ILS had
LIS grade 2 or 3; and only those with typical MDS facial
dysmorphisms had LIS grade 1. The authors deﬁned a
telomeric MDS critical region of 400 kb that is consis-
tently deleted in patients with ILS andMDS. The region
contains eight genes: PRP8, RILP, SREC, PITPNa, SKIP
MYO1C, CRK, and 14-3-3.
Haploinsufﬁciency of these genes in addition to LIS1
constitutes a contiguous-gene–deletion syndrome that
contributes to both the facial and the brain dysmorph-
isms seen in MDS. The study by Cardoso et al. (2003)
also conﬁrmed that the severest form of LIS (complete
agyria) is seen only in patients with MDS. The authors
used PCR to map deletions gene by gene in patients
with MDS and complete agyria. Two genes (CRK and
14-3-3) were speciﬁcally deleted in patients who had
MDS with the most severe form of LIS, indicating that
deletion of one or both of these genes in addition to
loss of LIS1 may be responsible for complete agyria in
MDS. Deletion telomeric of 14-3-3 causes no change
in phenotype; however, deletion from the telomere
through the MDS critical region without mutations
or deletions of LIS1 is associated with mental retar-
dation. These patients did not have lissencephaly, in-
dicating the presence of a gene or genes that may be
involved in or responsible for mental retardation (Car-
doso et al. 2003).
Human 17p13.3 and Mouse 11
The human data led to the determination of this MDS
critical region. However, it is difﬁcult, on the basis of
human data, to directly assess the contribution of each
gene in the MDS critical region to the phenotype. ILS
and MDS are rare, making it nearly impossible to an-
alyze a large enough panel of patients to allow for
deﬁnitive conclusions. The mouse may be the most ap-
propriate model to dissect and understand human con-
tiguous-gene–deletion syndromes for the following rea-
sons: the human and mouse genomes are similar in terms
of number and order of genes of 1–2 Mb; humans and
mice develop in a similar manner; and it is possible to
speciﬁcally modify the mouse genome by gene-targeting
and transgenic technologies.
Fortuitously, the genetic organization of the MDS
critical region appears to be reasonably conserved from
human to mouse, in that most of the known or predicted
human genes have a mouse counterpart and are present
in almost the same order in both organisms. The region
deleted in MDS is located on a region of ∼2.9 Mb (from
Figure 1 Schematic of the syntenic regions on human chromosome 17p13.3 and mouse chromosome 11. The distance between genes is
approximated for clarity. The order and position of genes was obtained from the Human Genome Project Ensembl Database and Celera. There
are some discrepancies between the two databases, and, when possible, these discrepancies were resolved by analysis of BACs (Cardoso et al.
2003).
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0.1 Mb to 2.9 Mb) on chromosome 17p13.3, extending
from LIS1 to the telomere (ﬁg. 1). Currently, 21 genes
have been identiﬁed (ﬁg. 1), and 28 genes have been
proposed by Ensembl predictions for 17p13.3. Within
this region, the MDS critical region appears to be lo-
cated between LIS1 and 14-3-3. The short arm of
human chromosome 17 corresponds to a region in the
middle of mouse chromosome 11 (75.2–77.3 Mb). This
region in the mouse is smaller (∼1.9 Mb) than in the
human, and homologues of all 21 known human genes
in 17p13.3 are present. Of the 28 proposed genes in the
humanMDS region, mouse homologues of all but 9 have
been found by Ensembl’s Blast analysis. In addition, there
are 11 proposed genes scattered throughout the region
in both the mouse and human that have not been char-
acterized or grouped by Ensembl predictions.
The genes from LIS1 to 14-3-3, corresponding to
the MDS region, are in the same order in mice and
humans. From SERPINF2 to PRP8 in the human ge-
nome, a potential region of duplication exists in the
form of proposed genes that are similar to other genes
in the region, but it is not known if these are functional
genes. This duplication is not found in the mouse ge-
nome. The region of 17p13.3 adjacent to 14-3-3 in
the human sequence, extending from ABR to DOC2B,
is present in the mouse, but it is removed from the
synteny block, placed centromeric to Rph3al, and in-
verted. Thus, all known genes in the MDS region are
present in syntenic regions of the mouse and human
genome, but there is some reorganization of adjacent
genes.
Phenotypes of Mice Created with Mutations in Genes
from the MDS Region
Null and conditional knockout alleles in the mouse have
been generated for Lis1 and Mnt, and null alleles have
been produced for Hic1 and 14-3-3. For Lis1 and
Pitpa, hypomorphic alleles also exist. The phenotypes
of these mice will be discussed in the order they occur
in the MDS region.
Lis1
LIS1 is a 45-kDa protein that encodes for a noncata-
lytic subunit of platelet-activating factor acetylhy-
drolase 1B (PAFAH1B), so the formal name for LIS1
is “PAFAH1B1” (Hattori et al. 1994). Although PAFAH
has been shown to have a variety of neuron-speciﬁc ef-
fects, it remains unclear how PAFAH functions in neu-
ronal migration. LIS1 has homologues in all eukaryotes.
Initial insight into the role of LIS1 in neuronal migration
came from identiﬁcation of a LIS1 homologue as the
gene mutated in the nuclear distribution mutant nudF
of the ﬁlamentous fungus Aspergillus nidulans (Xiang
et al. 1995). NudF was shown to genetically interact
with cytoplasmic dynein to properly position the nucleus
within growing germlings. On the basis of these studies,
it was proposed that LIS1 regulates dynein function to
cause nuclear movement. Several studies have conﬁrmed
that LIS1 homologues regulate cytoplasmic dynein
in Aspergillus, Drosophila, and mammalian organisms
(Willins et al. 1997; Liu et al. 1999; Smith et al. 2000),
so it is believed that loss of this regulation may also be
involved in the defects in neuronal migration that are
associated with LIS1 mutations in humans.
To further understand LIS1 function and to evaluate
its role in neuronalmigration, twomutant alleles inmouse
Lis1 were generated in our laboratory. The knockout al-
lele (Lis1ko or Pafah1b1-loxP) is a complete null, and the
conditional knockout allele (Lis1cko or Pafah1b1-neo) is
hypomorphic, because of disruption of transcription or
splicing by the insertion of a phosphoglycerate kinase–
neomycin cassette from the targeting vector into the sec-
ond intron (Hirotsune et al. 1998). Complete loss of Lis1
in Lis1ko homozygotes results in early embryonic lethality.
By mating mice to obtain various combinations of alleles,
mice were generated with graded reduction in Lis1 dos-
age. As Lis1 dosage decreased, mice exhibited increased
disorganization of the cortical layers, hippocampus, and
olfactory bulb, because of migration defects (Hirotsune
et al. 1998; Gambello et al. 2003). The cortex had no
discernible lamination andwas thinner than thewild type.
As Lis1 dosage decreased, neuronal migration rates
were also dramatically reduced both in vivo and in vitro
(Hirotsune et al. 1998; Gambello et al. 2003). In vivo
analysis of neuronal migration was performed using
BrdU birth-dating. BrdU is incorporated into the newly
synthesized DNA of S-phase cells and is often used to
estimate the fraction of cells in S phase. During cortical
development in mice (E14.5–E17.5), neuronal precursor
cells divide in the ventricular zone and migrate through
the cortex to their ﬁnal position, as a function of time
from birth date. A subset of proliferating neurons can be
labeled with BrdU at one time point, and animals can be
killed at later times to analyze the migration rate or dis-
tance traveled from the ventricular zone. The Lis1/ko
(∼50% LIS1 protein) mice appear normal as adults, but
BrdU birth-dating analysis in vivo shows that these neu-
rons have reduced migration rates compared with the
wild type. After a prolonged period, they reach their
appropriate destination. The most severe genotype,
Lis1cko/ko (∼35% of LIS1 protein), exhibits a broader and
more disorganized band of migrating neurons that re-
main closer to the ventricular zone. The migration rates
were also tested in vitro by measuring the distance that
cerebellar granule cells migrated along neurites from cell
clusters plated on laminin. The wild-type neurons
migrated four times farther than those of the Lis1/ko
mice. There was no difference in mean neurite length
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(Hirotsune et al. 1998). These results conﬁrmed that the
neuronal migration phenotype seen in ILS is the result
of dosage sensitivity and haploinsufﬁciency. Further-
more, Lis1cko/ko mice provide a model that reiterates
many components of the human disease: disorganized
cortical layers, generalized neuronal heterotopias, en-
larged ventricles, and microcephaly (Gambello et al.
2003). Another mouse mutant was produced with a de-
letion of the ﬁrst exon and part of the LIS1 promoter
(Cahana et al. 2001). A short LIS1 protein is produced
in these mice, presumably because of initiation at the
second methionine codon of LIS1. The protein appears
to be a hypomorphic or combined hypomorphic/neo-
morphic allele, since heterozygotes are less severely af-
fected than the Lis1ko heterozygotes, but homozygotes
display early embryonic lethality similar to that of Lis1ko
homozygotes.
In addition to its contribution to neuronal migration,
there is evidence that LIS1 participates in cell division.
In vitro cell culture studies indicate that LIS1 is localized
at prometaphase kinetochores and at the cell cortex of
dividing cells, both known binding sites for cytoplasmic
dynein. Overexpression of LIS1 in ﬁbroblasts results
in mitotic defects, such as spindle misorientation and
metaphase chromosome misalignment. When LIS1 is
depleted, either by application of LIS1 antisense oligo-
nucleotides or microinjection of anti-LIS1 antibody, mi-
totic defects are also observed (Faulkner et al. 2000). In
the Lis1cko/ko mice, the brains are reduced in size. This
may be the result of defects in neuronal proliferation
or differences in survival. BrdU birth-dating analysis
of Lis1cko/ko mice suggested that they have fewer prolif-
erating neuroblasts and more apoptotic cells in the ven-
tricular zone than do wild-type mice (Gambello et al.
2003). Both mechanisms are likely to contribute to a
reduction in the number of neuronal precursors, leading
to the hypothesis that, in addition to neuronal migration
defects in lissencephalic brains, deﬁciencies in the genesis
of neuronal progenitors may also be responsible for
some aspects of the brain phenotype in ILS and MDS.
The histological defects in the mouse were associated
with motor and cognitive impairments and increased
susceptibility to seizures. Lis1/ko mice were impaired on
a rotarod test and a spatial learning version of theMorris
water task (Paylor et al. 1999). The behavioral tests
indicate that defects in neuronal migration and, perhaps,
neurogenesis produced by Lis1 haploinsufﬁciency have
an impact on certain complex behavioral responses.
Neuronal migration defects also affected the hippocam-
pus of Lis1/ko mice, which appeared disorganized, with
loosely packed granule cells as well as discontinuities
and splitting of the pyramidal cell layer, which included
cells that are normally found in other regions. When
neurons were impregnated with silver nitrate by the
Golgi method, these heterotopic pyramidal cells displayed
a signiﬁcantly smaller dendritic arbor than was seen in
wild-type or properly localized Lis1/ko neurons. Electro-
physiological studies conﬁrmed that Lis1/ko mice were
more susceptible to seizures. Enhanced excitability and
disorganized ﬁeld potentials were seen in the Lis1/ko hip-
pocampus, in addition to hyperexcitability to electric
stimulation (Fleck et al. 2000). These integrative behav-
ioral and electrophysiological studies of Lis1/ko mice
provide a more comprehensive picture and relate the
defects in neuronal migration to mental retardation and
seizures seen in the patients with ILS.
Overall, the Lis1/ko and Lis1cko/ko mice are excellent
models for classical lissencephaly that reiterate many of
the histological and behavioral defects, although not at
the same dose reduction as in the human. In humans, a
50% reduction of LIS1 in heterozygotes results in severe
neuronal migration defects and lissencephaly. By con-
trast, severe defects analogous to human lissencephaly
are seen only in Lis1cko/ko mutants, which have !50% of
wild-type Lis1 levels. These differences may be the result
of more complicated development and longer migration
in the human brain than in the mouse brain.
Mnt
The Max network consists of a group of transcription
factors whose combination of interactions result in gene-
speciﬁc transcriptional activation or repression that af-
fects cell proliferation, differentiation, and death. To ac-
complish these tasks, Max forms heterodimers, through
basic helix-loop-helix zipper motifs, with Myc and Mad
protein family members, as well as the Mnt and Mga
proteins. The biosynthesis of the Max-interacting pro-
teins is strictly regulated, and they have short half-lives,
whereas Max is stable and constitutively expressed (for
a comprehensive review on theMyc/Max/Mad network,
see Grandori et al. [2000]). The regulation and role of
Max in this network depends upon Max-interacting
proteins. Myc plays a central role in promoting prolif-
eration and, consequently, in inducing neoplastic disease.
Myc:Max heterodimers activate and repress transcrip-
tion at certain target promoters to advance proliferation
and block terminal differentiation. Mad:Max hetero-
dimers appear to act as an opposing force to Myc:Max;
Mads are transcriptional repressors with antiprolifera-
tive effects produced in a variety of cell types upon dif-
ferentiation. The roles of Mnt and Mga are less clearly
deﬁned. Mnt displays similarities to Mad, in that Mnt
can recruit the mSin3 corepressor complex to repress
transcription in some cell types, and Mnt can prevent
Myc/Ras transformation of primary cells.
Transgenic mice or mice with knockouts of Mad net-
work members have not completely clariﬁed the roles of
these proteins in development. A null mutation in c-Myc
or N-Myc is lethal in homozygous mice at E.10–E.12.
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The embryos were smaller and were retarded in devel-
opment, and they had abnormalities of the heart, peri-
cardium, and neural tube (for review see Davis and Brad-
ley [1993]). The inhibitory effects of Mad and Mnt on
cell proliferation were demonstrated in vivo using mice
that expressed a transgene of either Mad or Mnt under
control of the b-actin promoter. Ubiquitous expression
of Mad in transgenic mice led to early postnatal lethality
and reduced body and organ weights; hematopoietic
cells and embryonic ﬁbroblasts isolated from these mice
showed a decreased proliferative capacity (Queva et al.
1999). Mnt overexpression results in a developmental
delay and death at ∼E8.5–E10.5 (Hurlin et al. 1997).
On the basis of these data, one could postulate that
knocking out Mnt or Mad might cause gigantism in
mice, because these factors would not be present to op-
poseMyc in its promotion of cell proliferation.However,
our data show that Mnt null mutant mice die perinatally
and are smaller than wild type. Depending upon the
genetic background, Mnt/ mice have defects in thymic
and craniofacial development, speciﬁcally skeletal ab-
normalities of the skull and cleft palate that are asso-
ciated with a small jaw (K.T. and A.W-B., unpublished
data). Patients with MDS as well as lissencephaly and
cleft palate have been reported (Kerner et al. 1999). It
may be that the cleft palate phenotype displayed by
Mnt/ mice is a model for the abnormalities in cranio-
facial development, including the small midface and jaw,
that are seen in patients with MDS.
Hic1
HIC1 is a transcription factor and candidate tumor
suppressor. HIC1 stands for “hypermethylated in can-
cer,” because, in many human cancers, HIC1 is subject
to gene silencing by abnormal methylation of its pro-
moter (Issa et al. 1997; Melki et al. 1999). HIC1 is
proposed to function as a transcriptional repressor that
can interact with C-terminal binding protein (CtBP) and
recruit histone deactylases (HDACs) (Deltour et al.
2002), but the target genes and pathways that are af-
fected by HIC1 activity have not been determined.
HIC1 is found in all adult tissues, but its embryonic
expression shows an interesting pattern. With the use of
in situ hybridization, HIC1 mRNA was detected in the
precursors of certain tissues that are affected in MDS.
For example, HIC1 is expressed in the ﬁrst branchial
arch, which gives rise to the maxillary and mandibular
components of the jaw and the face. Further HIC1 ex-
pression is found in the mesenchyme surrounding pe-
ripheral nerves, adjacent to epithelial buddings for the
nose, salivary glands, and pharyngeal pouches, and,
transiently, in early corneal development. Notably, the
mesenchyme that surrounds the infolding nasal epithe-
lium was positive for HIC1 mRNA. HIC1 was also de-
tected in the limb mesenchyme that surrounds the skel-
etal condensations and later in distinct rostral and caudal
digit anlagen. Other regions of HIC1 expression include
the lateral body wall and the developing gut and kidney
(Grimm et al. 1999).
Hic1 knockout mice die perinatally and exhibit a
range of gross developmental defects, such as acrania,
exencephaly, cleft palate, limb abnormalities, and om-
phalocele (Carter et al. 2000). No disorganization of the
cerebral cortex or neuronal migration defects are ob-
served. Hic1/ embryos are generally smaller than wild-
type embryos and are underdeveloped, but this may be
secondary to the severe developmental abnormalities.
Heterozygous Hic1 mutants have no distinctive devel-
opmental phenotype, as is true of Mnt heterozygotes,
but are predisposed to malignant tumors (Chen et al.
2003). The craniofacial defects include eye and jaw ab-
normalities, truncated or open secondary palate, shorter
snouts, and lower-set, less developed ears. Is this the
mouse version of the craniofacial defects seen in MDS
(short nose with upturned nares, thickened upper lip
with a vermilion upper border, widely spaced eyes, low
ears, and small jaw), as argued elsewhere (Carter et al.
2000)? The evidence is ambiguous at this point, because
Hic1 heterozygotes have no distinctive facial phenotype,
whereas, in humans, haploinsufﬁciency of either one or
multiple genes is responsible for facial dysmorphisms.
However, the knockout mouse does provide evidence
that Hic1 plays a role in craniofacial development.
Some Hic1/ embryos have smaller and dysmorphic
hind limbs and digits. Although these abnormalities do
not exactly replicate the MDS phenotype (clinodactyly,
camptodactyly, and polydactyly), they do suggest that
Hic1 is important for proper limb and digit develop-
ment. Hic1/ embryos also display ventral body wall
defects, such as omphalocele, in which intestinal loops
are seen outside the body cavity. In mouse development,
the midgut grows in the body stalk while the abdominal
cavity expands; at ∼E16.5, the midgut returns to the
body cavity, folding and rotating, and the ventral body
wall fuses. In humans, rapid growth of the midgut
around the 6th wk causes the intestine to herniate
through the umbilical ring; in the 10th wk, the intestine
returns to the abdominal cavity, and the umbilical ring
fuses. Patients with MDS have presented with omphal-
ocele and umbilical hernias. Abdominal wall defects re-
sult from the failure of the mesoderm to replace the body
stalk. This, in turn, causes insufﬁcient outgrowth and
increased diameter of the umbilical ring. The similarities
between the omphalocele in the Hic1/ embryo and in
patients with MDS underscore the possible role of Hic1
in this aspect of the MDS phenotype.
Why is there no heterozygous phenotype in Mnt and
Hic1 mutants? It is possible that the craniofacial defects
of MDS cannot occur without heterozygous deletion of
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both Hic1 and Mnt or, perhaps, the loss of these two
genes as well as other genes. Defects in the heterozygotes
might also be subtle, as are neuronal migration defects
in heterozygous mouse models. Production of Hic1/Mnt
double heterozygotes in the mouse would help to address
these questions.
Phosphatidylinositol Transfer Protein a (PITPa)
PITPa is important for normal brain function, since
reductions in PITPa mRNA levels were found in the
spontaneous mouse mutant vibrator (vb). Described in
1982, vb carries an autosomal recessive mutation that
causes an unusual rapid whole-body action tremor that
begins around postnatal day 11 in homozygotes (Wei-
mar et al. 1982). The tremor was attributed to degen-
eration of speciﬁc neurons in the spinal cord and, later,
in the brainstem and cerebellum. It remains to be de-
termined why only speciﬁc neurons in vb mice are sen-
sitive to PITPa reduction. The vb neuropathology
consists of progressive degenerative changes, with the
appearance of dilated endoplasmic reticulum in cell bod-
ies, dendrites, and axons. The neurons eventually de-
velop severe intracellular vacuolation and undergo
chromolysis (Weimar et al. 1982). Depending on the
genetic background, the life spans of homozygous mice
may vary from 30 to 1160 d. The vb mutation was
cloned using positional complementation. The cause of
the vb mutation is a retroposon insertion in Pitpa that
interferes with normal RNA accumulation of the gene.
Reduced levels of PITPa protein to 60% and 20% of
those in wild-type mice were seen in vb heterozygotes
and homozygotes, respectively. The vb heterozygotes dis-
play no obvious phenotypic abnormalities (Hamilton et
al. 1997).
PITPs exist in all eukaryotes, from yeast to humans.
Their role in membrane trafﬁcking is essential during
regulated exocytosis, biogenesis of secretory vesicles/
granules, and intra-Golgi transport. PITPs are also nec-
essary for inositol lipid signaling via phospholipase C
and phophoinositide 3 kinases (Cockcroft 2001). Re-
duction of PITPa protein may cause misregulation of
downstream signaling pathways or a block in intracel-
lular transport. PITPa knockout mice exhibit spinocer-
ebellar disease, hypoglycemia, and intestinal and hepatic
steatosis. Alb et al. (2003) suggest this phenotype is due
to defective trafﬁcking of lipids and fatty acids from the
endoplasmic reticulum. Heterozygous PITPa mice have
no distinctive phenotype.
It is unclear whether PITPa is involved in any of the
neuronal defects displayed by patients with MDS. Trem-
ors or neurodegeneration have not been described in
these patients, which may be a consequence of their re-
duced life span although neurodegeneration in vb mu-
tants appears to be related to onset of physical activity.
It may also indicate that, for neurodegeneration to occur,
PITPa must be reduced to levels !50% of normal, as is
the case for the vb homozygote.
Crk
Crkwas originally identiﬁed in chicken tumor samples
as a viral oncogene that caused an increase in tyrosine-
phosphorylated proteins. After the realization that Crk
was a cellular gene, human and mouse Crk and Crk-
like genes (CRKL in humans and Crkol in mice) were
cloned. From there, a large number of studies have in-
vestigated the role ofCrk family members in signal trans-
duction. Crk/CRKL proteins form selective multiprotein
complexes that produce different biological outcomes in
response to a variety of extracellular stimuli (a review
of Crk-family binding proteins and biological roles has
been published elsewhere [Feller 2001]). The Crk family
plays a major role in the reorganization of the cytoske-
leton during cell migration, in cell-shape changes, and
in the integration of growth and adhesion signals at focal
adhesions. Also, Crk/CRKL are activated downstream
of integrins and migration-inducing factors.
Both CRK and CRKL are located within deletion
regions for syndromes with craniofacial phenotypes. Al-
though CRK maps to the common deletion region for
MDS, CRKL maps within that for DGS/VCFS, on hu-
man chromosome 22q11. The phenotype of DGS/VCFS
includes cardiac anomalies, facial dysmorphisms, thymic
hypoplasia, cleft palate, learning dysfunction, and hy-
pocalcemia. DGS/VCFS is the result of developmental
defects involving the third and fourth pharyngeal
pouches, the result of defective migration of the neural
crest cells during the 4th wk of embryogenesis.
During mouse development, Crkol is highly expressed
in neural crest–derived tissues. The neural crest contrib-
utes to proper formation of connective tissue and skeletal
structures of the head. Mice homozygous for a targeted
null mutation in Crkol exhibit multiple defects in cranial
and cardiac neural crest derivatives, including cranial
ganglia, aortic arch arteries, cardiac outﬂow tract, thy-
mus, parathyroid glands, and craniofacial structures
(Guris et al. 2001). Less than 2% ofCrkol/mice survive
past birth. Those that do have recognizable abnormalities
of facial features, such as ocular hypertelorism and a
wider, shorter skull. Because migration and early expan-
sion of neural crest cells is normal in Crkol/ mice, a
postmigratory defect in differentiation, survival, or func-
tion of speciﬁc neural crest cells is most likely affected.
The defects seen in Crkol/ mice argue against re-
dundant functions for Crk and Crkol. However, this
does not exclude the hypothesis that Crk may be nec-
essary for neural crest migration or may be part of other,
possibly cooperative, signaling pathways for neural dif-
ferentiation, survival, and function. Overexpression of
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v-Crk in sensory, motor, and enteric neurons potentiates
motor neuron survival and axonogenesis, even in the
absence of exogenous growth factor. In this system, v-
Crk also increased the volume of motor end plates and
the complexity of neuromuscular junctions (Weinstein
et al. 1999). This study provides important in vivo ev-
idence of the role of Crk family members in developing
neurons. The development of a knockout mouse will be
important to the understanding of whether loss of Crk
also affects neural crest cells and the tissues derived from
them or whether loss of Crk has some other unpredicted
role in development.
14-3-3
The 14-3-3 family of genes is found in all eukary-
otic cells. These highly conserved regulatory mole-
cules bind to phosphoserine/phosphothreonine motifs
in a sequence-speciﬁc manner. Through this interaction,
14-3-3 proteins are known to have 1100 binding part-
ners and to be involved in modulating a multitude of
cellular functions, including signal transduction, cell cy-
cle control, apoptosis, stress responses, vesicular trans-
port, and malignant transformation (Skoulakis and
Davis 1998; Fu et al. 2000). 14-3-3 proteins can reg-
ulate their binding partners by any of the following
methods: affecting the target proteins’ ability to bind
other partners, changing the proteins’ rate of nuclear
transport, altering their catalytic activity, protecting
them from proteolysis or dephosphorylation, or provid-
ing an adapter/scaffold function to bridge protein inter-
actions (Tzivion and Avruch 2002).
Separate genes encode for the seven 14-3-3 isoforms
known in mammals, each named with a Greek letter (b,
, g, h, j, t, or z). Ten isoforms are found in plants and
two each in yeast, Drosophila, and Caenorhabditis ele-
gans. The 14-3-3 proteins can form homo- and heter-
odimers, and mutant forms of these proteins can act as
dominant inhibitors in vivo. The dimerization state may
act to cross-link two proteins, to generate speciﬁcity, or
to increase the afﬁnity for one protein (Yaffe et al. 1997).
The degree of speciﬁcity and redundancy within the
14-3-3 family is not known, because the key residues in
the ligand-binding domain are conserved among all the
proteins. However, variable residues around the ligand-
binding domain could confer speciﬁcity. In vitro, 14-3-3
proteins show variable afﬁnities to certain target pro-
teins, and it has been proposed that slight changes in
binding afﬁnity may have biological relevance in vivo.
Furthermore, phosphorylation and protein level, both
temporal and spatial, may modulate dimerization and
function of 14-3-3 proteins. Since heterodimers can
form, there is great potential for exquisite speciﬁcity for
target binding that will require further biochemical and
genetic analysis.
14-3-3 proteins were initially discovered in 1967 in a
biochemical screen for brain-speciﬁc proteins (Moore
and Perez 1967). With the use of starch electrophoresis,
14-3-3 proteins were easily detected because of their rel-
ative abundance (∼1% of proteins) in the brain. In 1996,
14-3-3 proteins were implicated as binding partners to
oncogenic proteins, and further research has focused
mainly on their role in cell cycle, apoptosis, and differ-
entiation (Jelinek et al. 1996; Liu et al. 1996). The var-
ious expression patterns of 14-3-3 isoforms in the brain
during mouse embryogenesis underscore their potential
signiﬁcance in neuronal development (Watanabe et al.
1993; McConnell et al. 1995). The 14-3-3 proteins are
also important in signaling and neuronal development
in Drosophila (Skoulakis and Davis 1998). 14-3-3
plays an important role in Drosophila eye development
by increasing the efﬁciency of RAS1 signaling (Chang
and Rubin 1997). Homozygous null mutants of leonar-
do (14-3-3z) die as mature embryos, and viable leonardo
mutants show olfactory learning deﬁcits correlated with
the level of expressed protein (Skoulakis andDavis 1996;
Broadie et al. 1997), supporting a role for 14-3-3 dosage
in neurons. These studies also suggest that haploinsuf-
ﬁciency of 14-3-3 in MDS may have negative effects
on neuronal development.
In our laboratory, a null allele of 14-3-3 was created.
Recently, we found thatmousemutants of14-3-3display
dose-dependent defects in neuronal development and mi-
gration (Toyo-oka et al. 2003). In both 14-3-3/ and
14-3-3/, the cortex and hippocampus form in the nor-
mal inside-out fashion, similar to developmental events
in Lis1/ko mice. The 14-3-3 heterozygotes show mild
disorganization in the hippocampus and thinning of the
cortex that becomes more severe with complete loss of
14-3-3. Neuronal precursor proliferation in the ventric-
ular zone that occurs between E12.5 and E15.5 is not
affected in either 14-3-3/ or 14-3-3/ mice, as de-
tected by BrdU analysis, but a threefold increase, com-
pared with wild type, in apoptotic cells in the cortex at
E12.5 of 14-3-3/may account for the cortical thinning.
Neuronal migration was also quantitated by BrdU birth-
dating analysis, which revealed that, as in Lis1 mutant
mice, the rate of neuronal migration decreases as the dose
of 14-3-3 is reduced.
Double heterozygotes of Lis1 and 14-3-3 were gen-
erated to test whether the similarity of phenotypes be-
tween Lis1 and 14-3-3 mutants signiﬁed a genetic
interaction necessary for proper neuronal migration.
Indeed, double heterozygotes of 14-3-3 and Lis1 dis-
play more-severe migration defects in both the cortex
and hippocampus than do single heterozygotes, provid-
ing genetic evidence that 14-3-3 may be responsible for
the most severe form of lissencephaly (complete agyria)
seen in MDS (Toyo-oka et al. 2003).
The genetic interaction seen in vivo between Lis1 and
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14-3-3 stimulated an investigation of how 14-3-3
works within the LIS1 pathway/complex to affect neu-
ronal migration (Wynshaw-Boris and Gambello 2001;
Gupta et al. 2002). LIS1 binds to cytoplasmic dynein
heavy chain (CDHC) and NUDEL, which is one of two
identiﬁed mammalian homologues of the nuclear dis-
tribution mutant nudE of A. nidulans (Niethammer et
al. 2000; Sasaki et al. 2000). Part of the regulation of
this complex depends upon phosphorylation of NUDEL
by CDK5, a kinase required for proper neuronal migra-
tion (Niethammer et al. 2000; Sasaki et al. 2000). CDK5
phosphorylates NUDEL in the region required for CDHC
binding and is thought to regulate activity or motility
of dynein in this manner (Sasaki et al. 2000). Two-hybrid
and immunoprecipitation experiments in yeast demon-
strated that phosphorylation of NUDEL by CDK5 is
necessary for 14-3-3 binding (Toyo-oka et al. 2003).
14-3-3may protect NUDEL from dephosphorylation by
PP2A phosphatase. NUDEL binds speciﬁcally to 14-3-3
but not to other 14-3-3 proteins. This interaction is im-
portant for proper localization of dynein, presumably
by maintaining NUDEL in the phosphorylated state so
that it can interact with dynein (Toyo-oka et al. 2003).
The study reported by Toyo-oka et al. (2003) dem-
onstrates the power of mouse genetics to determine the
contribution of each gene to a complicated phenotype
by combining mouse mutants. We must await the cre-
ation of a Crk null allele to test whether CRK also plays
a role in neuronal migration and can genetically interact
with LIS1 and 14-3-3.
Other Genes with Functions that May Be Important
for MDS
The remaining 15 known genes in the 17p13.3 region
are brieﬂy described in table 1. Some of the genes in this
region code for proteins that run the gamut of cellular
functions that are important for development, including
proliferation, migration, cytoskeletal organization, dy-
nein regulation, lipid signaling, membrane trafﬁcking,
and transcriptional control (see table 1 for references).
Five of the eight genes identiﬁed as part of anMDS critical
region remain to be discussed: PRP8, RILP, SREC, SKIP,
and MYO1C (Cardoso et al. 2003). We can speculate
that some of these genes may contribute to the MDS
phenotype. PRP8, the most conserved splicing factor, reg-
ulates spliceosome activity. Neuronal migration relies on
the integrity and function of the cytoskeleton, as we dis-
cussed in the “Lis1” section above. CRK and SKIP are
proposed to modulate changes in the cytoskeleton. De-
ﬁciencies in the above genes could affect craniofacial de-
velopment and neuronal migration by disrupting prolif-
eration, migration, or cytoskeletal integrity.
Another group of genes in this region are involved in
membrane trafﬁcking and exocytosis. These genes may
be important for neuronal homeostasis and transmitter
release. RILP recruits dynein-dynactin motor complexes
to Rab7-containing late endosomes and lysosomes. Thus,
RILP could interact with the LIS1/dynein complex,
thereby modulating the latter’s function, although it is
not known whether such interactions exist. MYO1C, a
member of the myosin I motor family, localizes at regions
of high actin concentration and within the Golgi appa-
ratus. Other genes involved in membrane trafﬁcking and
exocytosis include SREC and PITPa. Haploinsufﬁciency
of these genes may cause mislocalization of membrane
components and misregulation of neurotransmitter re-
lease. This disruption in homeostasis could result in neu-
ronal loss or, possibly, seizures.
Conclusions and Speculation
The genetic analysis of ILS and MDS in 30 patients
revealed that CRK and 14-3-3 were exclusively deleted
only in those patients with complete agyria, implicating
one or both genes in cortical development. Furthermore,
the data show that, as the deletion size increased to
include the newly deﬁned telomeric MDS critical region,
the lissencephaly and facial phenotype worsened. The
consensusMDS facial phenotype was also seen onlywith
deletion of CRK and 14-3-3 (Cardoso et al. 2003).
Heterozygous deletion of both Lis1 and 14-3-3 in the
mouse produces a greater defect in neuronal migration
than do single heterozygous mutations (Toyo-oka et al.
2003). The human and mouse data indicate that the
severe neuronal migration phenotype (complete agyria)
seen in patients with MDS may be due to deletion of
LIS1 and 14-3-3 although it remains to be determined
whether CRK or other genes in the MDS critical region
play a role in cortical development.
Concerning the MDS facial dysmorphisms, it remains
uncertain whether the distinctive facial phenotype is a
result of lissencephaly or haploinsufﬁciency of multiple
genes important for craniofacial development. One
patient, who presented with mild mental retardation
but without lissencephaly and facial dysmorphisms,
had a deletion from the telomere through CRK, 14-3-3,
and other genes in the MDS critical region (Cardoso et
al. 2003). However, we cannot draw meaningful con-
clusions without analysis of additional patients with
17p13.3 deletions. Patients with mild facial abnormal-
ities have LIS grade 2 or 3, whereas only patients with
LIS grade 1 (complete agyria) have consensus MDS fa-
cial phenotypes. The development of additional mouse
knockouts of other genes in the MDS critical region,
especiallyCrk,will help dissect the genetic contributions
to the craniofacial defects seen in patients with MDS.
From the study of these various mouse mutants, spe-
ciﬁc directed questions can be asked about the rela-
tionship between deletion size, haploinsufﬁciency effect,
Table 1
Genes Located on Human Chromosome 17p13.3
Gene Description
LIS1 (PAFAH1B)a Noncatalytic subunit of platelet-activating factor acetylhydrolase; part of conserved dynein regulatory pathway; when mutated or deleted,
causes classical lissencephaly (Hirotsune et al. 1998; Wynshaw-Boris and Gambello 2001)
MNTa Basic-helix-loop-helix zipper transcription factor; part of the Max network affecting cell proliferation, differentiation, and death (Gran-
dori et al. 2000)
SRR Serine racemase; catalyzes synthesis of D-serine from L-serine; possible roles in neurotransmitter synthesis and signaling (De Miranda et
al. 2000; Snyder and Kim 2000)
HIC1a Transcription factor; interacts with C-terminal binding protein and recruits histone deacytelases to repress transcription; Hic1/ mice die
perinatally and exhibit a range of gross developmental defects (Carter et al. 2000; Deltour et al. 2002)
OVCA2 (DPH2L) Candidate tumor suppressor genes; diphthamide biosynthesis protein 2–like; ubiquitously expressed but reduced mRNA levels in ana-
lyzed ovarian tumors and tumor cell lines (Schultz et al. 1996; Wiper et al. 1998; Prowse et al. 2002); inhibits proliferation, suggested
to be a growth regulator (Phillips et al. 1996; Liu et al. 2000)
RPA1 Replication protein A1; ubiquitous eukaryotic gene with roles in DNA replication, repair, and recombination (Umezu et al. 1998)
PEDF (SERPINF1) (SERPINF2) Pigment epithelium–derived factor; factor that promotes survival, differentiation, and neuroprotection in a variety of neuronal cell culture
models, including cerebellar granule cells, photoreceptors, and spinal cord motor neurons (Araki et al. 1998; Houenou et al. 1999;
Jablonski et al. 2001; Yabe et al. 2001)
PRP8b Most highly conserved splicing factor; important for coordination of multiple processes in spliceosome activation (Kuhn et al. 2002)
RILPb Rab7-interacting lysosomal protein; involved in the recruitment of functional dynein-dynactin motor complexes to Rab7-containing late
endosomes and lysosomes (Jordens et al. 2001)
SRECb Scavenger receptor expressed by endothelial cells; mediates endocytosis of modiﬁed lipoproteins, such as acetylated or oxidized low-den-
sity lipoprotein (Adachi and Tsujimoto 2002)
PITPaa,b Important for inositol lipid signaling and membrane trafﬁcking; gene mutated in vibrator mouse (Hamilton et al. 1997; Cockcroft 1999)
SKIPb Skeletal muscle and kidney enriched inositol phosphatase; may negatively regulate the actin cytoskeleton through hydrolyzing inositol
signaling (Ijuin et al. 2000)
MYO1C (MYO1E, MYR-3)b Intestine-speciﬁc single-headed member of the myosin I motor family; localized at adherens-type intercellular junctions, regions of high
actin concentration, and Golgi apparatus (Stofﬂer et al. 1998; Skowron and Mooseker 1999)
CRK I, CRK IIb SH2/SH3 adaptor molecules; isoforms produced by alternate splicing; integrates many signal transduction pathways to affect changes in
the cytoskeleton during cell growth and migration (Feller 2001)
14-3-3a,b Part of large family of proteins that are involved in many cellular functions; regulates binding partners by binding to speciﬁc phosphoser-
ine/phosphothreonine motifs (Yaffe et al. 1997; Fu et al. 2000; Tzivion and Avruch 2002)
ABR Active breakpoint cluster region (BCR)–related gene; may function with BCR and Rho family members in signaling; double homozygous
mice (ABR//BCR/) exhibit vestibular dysgenesis and glial cell abnormalities (Tan et al. 1993; Chuang et al. 1995; Kaartinen et al.
2001; Kaartinen et al. 2002)
TIMM22 Predicted gene; mitochondrial import inner membrane translocase subunit (Ensembl gene number ENSG00000108911)
NXN Considered an ambiguous gene; Blast analysis suggests it is similar to mouse nucleoredoxin, which regulates protein activity and gene
expression through thiol-mediated oxidoreduction (Hirota et al. 2000)
DOC2B Implicated in synaptic vesicle exocytosis; homologue DOC2A is brain speciﬁc, but DOC2B is expressed ubiquitously and may have other
developmental functions (Verhage et al. 1997; Korteweg et al. 2000)
RPH3AL Rabphilin-like gene; similarities suggest involvement in endocrine exocytosis and interactions with cytoskeleton (Smith et al. 1999)
NOTE.—Genes are shown in order from LIS1 to the telomere.
a Mouse models have been created.
b Genes identiﬁed as being within the critical region for Miller-Dieker syndrome (Cardoso et al. 2003).
Yingling et al.: Mouse Models of Miller-Dieker Syndrome 485
and phenotype. Double heterozygotes might be infor-
mative if two genes interact in the same pathway or if
haploinsufﬁciency of both genes compounds the phe-
notype. For example,Hic1- andMnt-deﬁcient mice each
have distinctive craniofacial defects, whereas the het-
erozygotes do not have any discernible phenotypic ab-
normalities. Double heterozygotes may reveal that hap-
loinsufﬁciency of both Hic1 and Mnt is necessary to
produce a defect in craniofacial development and would
suggest that multiple genes contribute to theMDS facial
phenotype. Alternatively, it is possible that responsibil-
ity is not restricted to one or two genes and that the
entire region must be deleted for the MDS phenotype
to develop. If this is the case, strategic deletions of var-
ying size within the MDS critical region in the mouse
will need to be generated using combinations of con-
ditional knockout alleles. With this strategy, a mouse
could be generated with a deletion of all the genes in
the region except Lis1. This would answer a long-stand-
ing question that has not been resolved by the patient
data: Is deletion of Lis1 necessary for the craniofacial
defects?
In considering the use of mouse models to analyze
haploinsufﬁciency in human disease, we must also con-
sider how to approach the analysis of milder phenotypes
in the mouse. The absence of a phenotype in hetero-
zygous mice may truly represent a lack of a discernibly
distinct phenotype, but alternative explanations are pos-
sible. For example, it may be that examination of these
mice has not been sufﬁciently rigorous, that certain
genes are not susceptible to dosage, or that there are
genetic background effects that mask the phenotype. To
discern subtle changes in phenotype and to make com-
parisons between mice, careful phenotypic analysis
must be applied. For example, the Lis1/ko mice appear
outwardly normal; however, thorough BrdU analysis at
various time points demonstrates slower rates of neu-
ronal migration in vivo (Hirotsune et al. 1998). In adult
mice, these neurons eventually reach a position close to
the proper destination. In the case of dysmorphism in
mice, detection of mild craniofacial defects may require
comprehensive skeletal measurements onmany animals,
using detailed and consistent standards that are applied
across mouse models.
The existence of seemingly normal heterozygousmice
also raises questions about whether mice are as sensitive
as humans to haploinsufﬁciency. To see a signiﬁcant
change in phenotype, dosage may need to be manipu-
lated to levels !50%. For example, two alleles exist for
Lis1: a null allele (Lis1ko) and a hypomorphic allele
(Lis1cko). Lis1 protein levels are ∼45% those of wild-type
mice in the Lis1/ko animals and 35% in the Lis1cko/ko
animals. This additional 10% reduction results in dra-
matic neuronal migration defects and shortened life
spans that appear to be more representative of the severe
ILS phenotype than are Lis1/ko mice (Gambello et al.
2003).
Genetic background effects can also mask distinctive
phenotypes in mice. vb and Mnt knockout mice have
strain-dependent phenotypes. The ability to control
strain background in mice will likely be an advantage
in studying the mechanisms of variability in humans,
since it is known that patients from the same family
with precisely the same deletion do not necessarily pre-
sent with the same features. If phenotypic modiﬁers are
mapped, they may implicate larger pathways that may
provide further insight into the range of phenotypes seen
in the human disease.
There is still much we need to understand about the
genes responsible for complex phenotypes in contigu-
ous-gene–deletion syndromes, such as MDS. Much of
what we learn will, by necessity, require careful study
of human patients. However, the utility of mouse mod-
els for reﬁning our understanding of the relationship
between gene function and phenotypes will greatly con-
tribute to these studies and will help to provide further
mechanistic insight into the developmental and genetic
pathways that contribute to these complex phenotypes.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Ensembl Genome Browser, http://www.ensembl.org (for order
and position of genes and for TIMM22 [accession number
ENSG00000108911])
Celera, http://publication.celera.com/humanpub/index.jsp (for
order and position of genes)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for DGS, ILS, MDS, and VCFS)
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